Pivotal Study of the FRED Stent System in the Treatment of Intracranial Aneurysms (FRED)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01801007 |
|
Recruitment Status :
Completed
First Posted : February 28, 2013
Results First Posted : October 9, 2020
Last Update Posted : March 8, 2021
|
Sponsor:
Microvention-Terumo, Inc.
Information provided by (Responsible Party):
Microvention-Terumo, Inc.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of the MicroVention Flow Redirection Intraluminal Device (FRED) system when used in the treatment of wide-necked intracranial aneurysms.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Intracranial Aneurysms | Device: Flow Re-Direction Endoluminal Device (FRED) | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 145 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | FRED |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Pivotal Study of the MicroVention Flow Re-Direction Endoluminal Device (FRED) Stent System in the Treatment of Intracranial Aneurysms |
| Study Start Date : | July 2013 |
| Actual Primary Completion Date : | January 2018 |
| Actual Study Completion Date : | January 2018 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
| Flow Re-Direction Endoluminal Device |
Device: Flow Re-Direction Endoluminal Device (FRED) |
Primary Outcome Measures :
- Percentage of Participants With Complete Occlusion of the Target Aneurysm and ≤50% Stenosis of the Parent Artery and an Alternative Treatment of the Target Intracranial Aneurysm (IA) Had Not Been Performed Within 12 Months [ Time Frame: 12 months ]The primary effectiveness endpoint has three components: 1) complete occlusion of the target aneurysm assessed by a core laboratory utilizing the Raymond-Roy Scale 2) ≤ 50% stenosis of the parent artery at the target (IA) using the Warfarin-Aspirin Symptomatic Intracranial Disease(WASID) criterion which is defined as greater than 50% luminal loss, 3) alternative treatment of the target IA is defined as re-treatment of the target aneurysm with an alternative treatment modality including open repair, endovascular placement of an additional stent or treatment of In-stent Stenosis observed. The Raymond-Roy Occlusion Classification has 3 responses, where Grade I is complete occlusion, no flow of contrast seen in the sac, Grade II is partial occlusion, some flow in the neck or sac, and Grade III is incomplete occlusion, apparent flow into the sac. Grade 1 indicates the best outcome.
- Percentage of Participants Who Experience Neurological Death or Major Ipsilateral Stroke Measured by the Modified Rankin Scale (mRS) and the National Institute of Health Stroke Scale (NIHSS) [ Time Frame: 12 months ]A major stroke is defined as a new neurological event that persists for > 24 hours and results in a ≥ 4 points increase in the NIHSS score compared to baseline or compared to any subsequent lower score. A major ipsilateral stroke is defined as that occurring within the vascular distribution of the stented artery. Neurologic death is defined as a death which has been adjudicated by the independent clinical events committee to have directly resulted from a neurologic cause.The NIHSS score ranges from 0 (no stroke symptoms) to 42 (severe stroke). mRS is 6 point assessment scale used to assess disability in patients who have suffered a stroke and is compared over time to check for recovery and degree of continued disability. The mRS score ranges from 0 (no disability) to 6 (death).
Secondary Outcome Measures :
- Percentage of Participants With Complete Occlusion of the Target Aneurysm on 12-month Angiography (Raymond-Roy 1) [ Time Frame: 12 months ]Complete occlusion of the target aneurysm assessed by a core laboratory. The Raymond-Roy class is an angiographic classification scheme for grading the occlusion (closure) of endovascularly treated intracranial aneurysms: class I: complete obliteration, class II: residual neck, class III: residual aneurysm.
- Percentage of Participants With ≥ 50% In-Stent Stenosis (ISS) at the Target Intracranial Aneurysm (IA) at 12 Months as Assessed by Angiography at the Independent Core Laboratory [ Time Frame: 12 months ]Stenosis of the parent artery at the target IA using the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) criterion which is defined as greater than 50% luminal loss
- Percentage of Participants in Whom an Unplanned Alternative Treatment of the Target IA Had Not Been Performed Within 12 Months [ Time Frame: 12 months ]Re-treatment of the target aneurysm with an alternative treatment modality including open repair, endovascular placement of an additional stent or treatment of In-stent Stenosis observed
- Percentage of Participants With Clinically Acceptable (90-100%) Occlusion of the Target Aneurysm, ≤ 50% Stenosis of the Parent Artery at the Target IA, and an Unplanned Alternative Treatment of the Target IA Had Not Been Performed [ Time Frame: 12 months ]This endpoint has three components: 1) clinically acceptable occlusion of the target aneurysm assessed by a core laboratory as percent occlusion (90%-100%) 2) ≤ 50% stenosis of the parent artery at the target IA using the WASID criterion which is defined as greater than 50% luminal loss, 3) alternative treatment of the target IA is defined as re-treatment of the target aneurysm with an alternative treatment modality including open repair, endovascular placement of an additional stent or treatment of In-stent Stenosis observed. The Raymond-Roy scale has 3 responses, where Grade I is complete occlusion, no flow of contrast seen in the sac, Grade II is partial occlusion, some flow in the neck or sac, and Grade III is incomplete occlusion, apparent flow into the sac.
- Percentage of Participants With Unsuccessful Delivery of the FRED [ Time Frame: Index Procedure ]Inability to deliver a FRED device to the target location
- Percentage of Participants That Had Procedure Related Serious Adverse Events With the FRED System [ Time Frame: 12 months ]A serious adverse event is any medical experience regardless of its relationship to the study treatment that occurs during participant enrollment in this trial that results in any of the following: (1) inpatient hospitalization or prolongation of a hospitalization; (b) persistent or significant disability or incapacity; (c) death of the study participant, or (d) necessitates an intervention to prevent a permanent impairment of a body function or permanent damage to a body structure. Procedure related events were associated with the index procedure, antiplatelet therapy, or follow up angiography.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 22 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Participant whose age ≥ 22 and ≤75 years
- Participant has single target aneurysm located in the internal carotid artery
- Participant sign and date an IRB/EC approved informed consent prior initiation of any study procedures
Exclusion Criteria:
- Participant who suffers from an intracranial hemorrhage in the last 30 days
- Participant who suffers from a subarachnoid hemorrhage in the last 60 days
- Participant with symptomatic extracranial mass or currently undergoing radiation therapy for tumor of the head and neck region
- Participant who is pregnant or breastfeeding
- Participant has an arteriovenous malformation (AVM) in the area of the target aneurysm
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01801007
Locations
Show 24 study locations
Sponsors and Collaborators
Microvention-Terumo, Inc.
Investigators
| Principal Investigator: | Cameron McDougall, MD | Johns Hopkins University |
Study Documents (Full-Text)
Documents provided by Microvention-Terumo, Inc.:
Documents provided by Microvention-Terumo, Inc.:
Statistical Analysis Plan [PDF] July 13, 2018
Study Protocol [PDF] November 14, 2016
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Microvention-Terumo, Inc. |
| ClinicalTrials.gov Identifier: | NCT01801007 |
| Other Study ID Numbers: |
CL12001 G120111 ( Other Identifier: FDA ) |
| First Posted: | February 28, 2013 Key Record Dates |
| Results First Posted: | October 9, 2020 |
| Last Update Posted: | March 8, 2021 |
| Last Verified: | February 2021 |
Additional relevant MeSH terms:
|
Intracranial Aneurysm Aneurysm Vascular Diseases Cardiovascular Diseases Intracranial Arterial Diseases |
Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases |